Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2009, vol. 18, nr 6, November-December, p. 585–588

Publication type: original article

Language: English

Evaluation of the Condition of the Larynx in Smokers with Schizophrenia

Ocena stanu krtani u palaczy chorujących na schizofrenię

Tomasz Zatoński1,, Maria Zalesska−Kręcicka1,, Maksim Tichonow2,, Jerzy Leszek2,, Katarzyna Zatońska3,, Ludmiła Waszkiewicz3,

1 Department and Clinic of Otolaryngology, Wroclaw Medical University, Poland

2 Department and Clinic of Psychiatry, Wroclaw Medical University, Poland

3 Department of Social Medicine, Wroclaw Medical University, Poland

Abstract

Background. Lower rates of cancer in schizophrenic patients than in the rest of population have been reported for almost a century. Results from studies of cancer rates in patients with schizophrenia are highly diverse.
Objectives. The purpose of this study was to analyze and appraise the evidence concerning the relationship between explicitly nicotine−dependent laryngeal lesions and schizophrenia.
Material and Methods. Endoscopic examination was conducted in 60 patients with a diagnosis of schizophrenia according to the International Classification of Diseases 10th revision (F 20, F 25) who smoked at least 20 cigarettes a day for at least 10 years and were hospitalized in the Clinic of Psychiatry of Wrocław Medical University.
Results. The results were compared with those of a population of adult smokers without mental disorders.
Conclusion. The presence of vocal cord atrophy was found more often in the group of schizophrenic patients.

Streszczenie

Wprowadzenie. Od wielu lat uważa się, że mimo palenia dużej liczby papierosów, osoby z rozpoznanymi zaburzeniami psychicznymi, głównie schizofrenią, rzadziej niż inni zapadają na choroby nowotworowe. Wyniki badań przeprowadzonych nad częstością raka u pacjentów ze schizofrenią są niejednoznaczne.
Cel pracy. Analiza związku między jednoznacznie tytoniozależnymi zmianami w obrębie krtani i schizofrenią.
Materiał i metody. Autorzy podjęli próbę zbadania z użyciem metody endoskopowej krtani 60 pacjentów palących od co najmniej 10 lat ponad 20 papierosów w ciągu doby ze stwierdzonymi zaburzeniami psychicznymi, głównie z grupy F 20–F 29 wg ICD−10, leczonych w Klinice Psychiatrii Akademii Medycznej we Wrocławiu.
Wyniki. Uzyskane wyniki porównano z grupą dorosłych palaczy, u których nie stwierdzono choroby psychicznej.
Wnioski. Stwierdzono częstszą obecność niedowładu strun głosowych u pacjentów chorych na schizofrenię.

Key words

laryngeal cancer schizophrenia cigarette smoking, vocal cord atrophy, VCA

Słowa kluczowe

rak krtani, schizofrenia, palenie tytoniu, niedowład strun głosowych

References (21)

  1. Gulbinat W, Dupont A, Jablensky A et al.: Cancer incidence of schizophrenic patients – results of record linkage studies in 3 countries. Br J Psychiatry 1992, 161, 75–85.
  2. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lonnqvist J: Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry 2001, 58, 573–578.
  3. Lawrence D, Holman CDJ, Jablensky A: Preventable physical illness in people with mental illness. The University of Western Australia, Perth 2001.
  4. Goldacre MJ, Kurina LM, Wotton CJ, Yeates D, Seagroatt V: Schizophrenia and cancer: an epidemiological study. Br J Psychiatry 2005, 187, 334–338.
  5. Dalton SO, Mellemkjaer L, Thomassen L, Mortensen PB, Johansen C: Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969–1993. Schizophr Res 2005, 75, 315–324.
  6. Grinshpoon A, Barchana M, Ponizovsky A et al.: Cancer in schizophrenia: is the risk higher or lower? Schizophr Res 2005, 73, 333–341.
  7. Dervaux A, Laqueille X: Smoking and schizophrenia: epidemiological and clinical features. Encephale 2008, 34(3), 299–305, Epub 2007.
  8. Ha PK, Califano J: The molecular biology of laryngeal cancer. Otolaryngol Clin North Am 2002, 3, 993–1012.
  9. Kambic V, Gale N: Significance of keratosis and dyskeratosis for classifying hyperplastic aberrations of laryngeal mucosa. Am J Otolaryngol 1986, 7, 323–333.
  10. Crissman JD, Visscher DW, Sakr W: Premalignant lesions of the upper aerodigestive tract: pathologic classification. J Cell Biochem Suppl 1993, 17F, 49–56.
  11. Putney FJ, O’Keefe JJ: The clinical significance of keratosis of the larynx as a premalignant lesion. Ann Otol Rhinol Laryngol 1953, 62, 348–357.
  12. Gale N, Michaels L, Luzar B, Poljak M, Zidar N, Fischinger J, Cardesa A: Current review on squamous intraepithelial lesions of the larynx. Histopathology 2008 Aug 25.
  13. Teunis MAT, Kavelaars A, Voest E, Bakker JM, Ellenbroek BA, Cools A R, Heijnen CJ: Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. FASEB J 2002, 16, 1465–1467.
  14. Torrey EF: Prostate cancer and schizophrenia. Urology 2006, 68, 1280–1283.
  15. Csatary LK: Chlorpromazines and cancer. Lancet 1972, 2, 338–339.
  16. Driscoll JS, Melnick NR, Quinn FR et al.: Psychotropic drugs as potential antitumor agents: a selective screening study. Cancer Treat Rep 1978, 62, 45–59.
  17. Nordenberg J, Fenig E, Landau M et al.: Effects of psychotropic drugs on cell proliferation and differentiation. Biochem Pharmacol 1999, 58, 1229–1236.
  18. Carrillo JA, and Benítez J: Are antipsychotic drugs potentially chemopreventive agents for cancer? Eur J Clin Pharmacol 1999, 55, 487–488.
  19. Park JK, Lee HJ, Kim JW et al.: Differences in p53 gene polymorphisms between Korean schizophrenia and lung cancer patients. Schizophr Res 2004, 67, 71–74.
  20. Havaki−Kontaxaki BJ, Kontaxakis VP, Christodoulou GN: Treatment of tardive pharyngolaryngeal dystonia with olanzapine. Schizophr Res 2004, 66, 199–200.
  21. Mellacheruvu S: Atypical antipsychotic drug−induced acute laryngeal dystonia. 2 case reports. J Clin Psychopharmacol 2007, 27(2), 206–207.